• Mashup Score: 0

    July 14, 2023 — BIOTRONIK announced the one-year subgroup results from the investigator-initiated BIOPACT randomized controlled trial (RCT), which were presented by principal investigator Dr. Koen Deloose at LINC, the Leipzig Interventional Course 2023. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo-18 Lux drug-coated balloon (DCB) catheter…

    Tweet Tweets with this article
    • @DAICeditor @BIOTRONIK_US No statistical difference observed across sub-analyses for #diabetes, #lesion length, calcium, bailout #stenting and #occlusions in head-to-head study comparing #Passeo18Lux #DCB to #InPactAdmiral DCB: https://t.co/jBGGNMldlB

  • Mashup Score: 0

    Background: Drug-coated balloon (DCB) therapy has been shown to be an effective alternative to drug-eluting stents as a revascularisation option, but usage of DCB varies widely between

    Tweet Tweets with this article
    • Just published #JAPSCJournal Interesting survey of ICs in APAC region (n=237) finds just >50% unaware of Int'l DCB consensus doc However, 74.3% will actively consider using #DCB for their patients undergoing PCI. https://t.co/YGBp16nmIZ @upulwick @Simoneccles66 @azeemlatib https://t.co/sNTf0qUE4E

  • Mashup Score: 0

    The second late-breaking clinical trial focused on Medtronic’s IN.PACT Admiral DCBs was presented by Daniel J. Bertges, MD, a vascular surgeon with the University of Vermont Medical Center in Burlington, Vermont, on Nov. 2. Bertges et al. performed a registry-based study using data from 300 patients who were treated at one of 43 different care sites across the United States. All patients were…

    Tweet Tweets with this article
    • Drug-coated balloons provide significant value in the battle against femoropopliteal disease @UHhospitals @UVMMedCenter @VIVAPhysicians @MDTVascular @Medtronic #DCB #PAD #cardiology https://t.co/NDgmYKAtzH